FDA Kicks Off Unapproved Drug Crack-Down With Carbinoxamine Enforcement
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is focusing initially on drugs containing the antihistamine carbinoxamine because of safety concerns in children.
You may also be interested in...
Low-profile Cough/Cold/Allergy Meds Target Of Latest FDA Push Against Unapproved Rx Drugs
The agency doesn't know the drugs' share of the market, but uncertainties about their safety and efficacy constitute an untenable risk for consumers, CDER compliance chief says.
Low-profile Cough/Cold/Allergy Meds Target Of Latest FDA Push Against Unapproved Rx Drugs
The agency doesn't know the drugs' share of the market, but uncertainties about their safety and efficacy constitute an untenable risk for consumers, CDER compliance chief says.
FDA Announces Withdrawal Of Unapproved Suppository Drugs For Nausea/Vomiting
Agency also is revoking NDA approval of King’s Tigan trimethobenzamide suppositories.